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MEASURING SOMATIC SYMPTOMS WITH THE CES-D 
TO ASSESS DEPRESSION IN CANCER PATIENTS AFTER 
TREATMENT, VALID OR NOT?
COMPARISON BETWEEN PATIENTS WITH HEAD AND NECK, 
GYNAECOLOGICAL, COLO-RECTAL, AND BREAST CANCER
C.P. van Wilgen 1,2,4, P.U. Dijkstra 1,2, R.E. Stewart 3 , 
A.V. Ranchor 3 , J.L.N. Roodenburg 1 
1. Department of Oral and Maxillofacial Surgery 2. Department of
Rehabilitation 3. Northern Centre for Health Care Research (NCG) 4. Pain





The prevalence of depression after cancer treatment is high. In literature
several authors have raised questions about assessing somatic symptoms
after cancer treatment to explore depression. They stated that the somatic
sequela are a consequence of cancer treatment and are therefor causing the
high depression rates in cancer patients. In this study we analysed the
somatic domain on a depression questionnaire (CES-D) in cancer patients
after treatment, in comparison with a control group, and we compared
between cancer groups. Data of 566 cancer patients (head and neck,
gynaecological, colo-rectal and breast cancer), and 255 randomly chosen
control patients were analysed. The total score of the CES-D on the domain
somatic retarded activity is significantly (p < 0.01) different for cancer
groups and control group. But the cancer groups score lower (colo-rectal
cancer) as well as higher (head and neck, breast) than the control group on
the somatic domain. We conclude that cancer patients are not a homogenous
group of patients concerning somatic sequela and therefor we can not find
evidence te remove somatic items from depression questionnaires for
patients after cancer treatment. 
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Introduction
Survival rates of several cancer types have become higher because of earlier
detection and better treatment properties (Brenner, 2002). As a consequence
more patients have to cope with the physical and emotional consequences of
the diagnosis cancer and the side effects of the treatment. In the last decade
more attention has been given to this group of patients. Important topics in
post-treatment cancer research are quality of life (Aaronson et al., 1992),
coping (Hassanein et al., 2001; Petticrew et al., 2002) depression (Hjerl et
al., 2003; Krishnan et al., 2002) somatic morbidity (Saffold et al., 2000; van
Wilgen et al., 2003), pain (Caraceni and Portenoy, 1999; Portenoy, 1992;
Zaza and Baine, 2002) and fatigue (de Jong et al., 2002; Morrow et al.,
2002). This research lead to a better understanding of the physical and
emotional problems after cancer treatment, and as a consequence treatment
programs have been developed, such as: rehabilitation programs (DeLisa,
2001), psycho-social interventions (Owen et al., 2001; Ronson and Body,
2002), pain management, (Portenoy and Lesage, 1999) and multidisciplinary
programs (Van Weert, 2004). 
An important outcome after cancer treatment is depression. The prevalence
of depression after cancer treatment is about 24 % (range 1.5 % to 50%) (Mc
Daniel et al., 1995). Depression affects quality of life, survival, length of
hospital stay, and therapy compliance (Bottomley, 1998, Hjerl et al., 2003;
Mc Daniel et al., 1995). It is therefor of clinical importance to recognise
depression in the post-treatment phase. 
According to the DSM IV a depressive episode is assumed if five (or more)
out of nine symptoms (Table 1) are present, additionally the symptoms
should be present during the same 2-week period and represent a change
from previous functioning (American Psychiatric Association, 1994).
Symptoms of a clinical depression in patients after cancer treatment can be
assessed through a clinical interview, a (semi)standardised interview or a
questionnaire. Questionnaires are used most frequently in cancer research. 
The prevalence of depression in cancer patients is related to type of cancer,
follow-up, medical illness, gender, and method of assessment (Beeber et al.,
1998; Bottom ley, 1998; Mc Daniel et al., 1995; Stommel et al., 1993).
Several authors have suggested that the high prevalence of depression after
cancer treatment is due to the fact that the somatic symptoms of depression
are identical with the somatic symptoms caused by the cancer treatment
                                                          
  Chapter 8
108
(Beeb er et al., 1998; Dugan et al., 1998; Krishnan et al., 2002; Visser and
Smets, 1998). They state that somatic symptoms should not be measured
when assessing depression in cancer patients. Some authors even removed
somatic items from depression questionnaires when measuring cancer
patients (Dugan et al., 1998; Visser and Smets, 1998). In the Hospital
Anxiety and Depression Scale somatic symptoms are not added to the
questionnaire (Zigmund and Snaith, 1983). Hard evidence for the hypothesis
that somatic symptoms should be removed in a depression questionnaire
when assessing cancer patients is virtually missing, although some studies
have been performed to explore this hypothesis. In one of the studies, to
explore the role of somatic items in cancer patients, the Zung self rating
scale was divided into a questionnaire with and without somatic items. The
outcome on the questionnaire with somatic items was about 5 % higher. The
authors stated that the Zung self rating scale has 5% more false-positive
depressed cancer patients when somatic items are assessed (Dugan et al.,
1998). After a factor analyses of the Zung Self Depression scale, Passik et al.
stated that fatigue is the only somatic item that is typically considered to be a
symptom of depression in cancer patients (Passik et al., 2000). While no
relationship between depression and fatigue was found by Visser et al. They
stated that fatigue is no valid criterion for depression if patients had received
radiation therapy (Visser and Smets, 1998). After analysing a structured
interview with cancer patients Akechi et al. described that eating disorders
and concentration problems are strongly related to depression while sleep
disorders and fatigue are not related to the depression but to the somatic
sequela of cancer treatment (Akechi et al., 2003). 
Several eating related side effects are described before (pain) and during
radiotherapy (xerostomia, dysphagia, pain) in head and neck cancer patients,
which may affect outcome on a depression questionnaire (Epstein et al.,
2001; Sehlen et al., 2003). 
From these performed studies no clear statement about the somatic items, in
the assessment of depression in cancer patient, can be made. The statements
about fatigue are even conflicting.
Aim of this study was to analyse the influence of somatic sequela on a
depression questionnaire (CES-D) in cancer patients after treatment in
comparison with a control group, and to analyse the different cancer types.
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Figure 1 DSM IV criteria for depression:
(1) depressed mood most of the day, nearly every day, as indicated by
either subjective report (e.g., feels sad or empty) or observation made
by others. 
(2) markedly diminished interest or pleasure in all, or almost all, activities
       most of the day, nearly every day 
(3) significant weight loss when not dieting or weight gain (e.g., a change
of more than 5% of body weight in a month), or decrease or increase in
appetite nearly every day. 
(4) insomnia or hypersomnia nearly every day
(5) psychomotor agitation or retardation nearly every day (observable by
others, not merely subjective feelings of restlessness or being slowed
down)
(6) fatigue or loss of energy nearly every day
(7) feelings of worthlessness or excessive or inappropriate guilt 
(8) diminished ability to think or concentrate, or indecisiveness, nearly
every day 
(9) recurrent thoughts of death (not just fear of dying), recurrent suicidal
ideation without a specific plan, or a suicide attempt or a specific plan
for committing suicide
Furthermore:
B.  The symptoms do not meet criteria for a mixed episode.
C.  The symptoms cause clinically significant distress or impairment in
      social, occupational, or other important areas of functioning.
D. The symptoms are not due to the direct physiological effects of a 
      substance (e.g., a drug of abuse, a medication) or a general medical 
      condition (e.g., hypothyroidism).
E.  The symptoms are not better accounted for by bereavement, i.e., after the
      loss of a loved one, the symptoms persist for longer than 2 months or are 
      characterised by marked functional impairment, morbid preoccupation
      with worthlessness, suicidal ideation, psychotic symptoms, or
      psychomotor retardation.
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Methods and material 
The CES-D is a short self-report scale designed to measure depressive
symptomatology (Radloff, 1977). The questionnaire is translated to Dutch
and contains 20 items divided in four domains: somatic retarded activity (7
items), depressed affect (5 items), positive affect (4 items), and interpersonal
affect (2 items) and two single items that complete the total score (Bouma et
al., 1995; Hanewald, 1987). The total score ranges between 0 – 60, a score of
16 or higher indicates a depressed symptomatology. The CES-D is often
assessed in patient with cancer. The psychometric properties of the CES-D
in cancer patients are described by several authors. Hann et al. (1999) found
an internal consistence of alpha .89 and the test-retest reliability was .51 (p <
0.001). The outcome in the validity analyses were all satisfactory. Concluded
was that the CES-D is appropriate for the use on clinical psycho-social
research (Hann et al., 1999). Although the relation with somatic symptoms
in cancer patients was, on our knowledge, never investigated with the CES-
D. In our study the CES-D was administered in patients at least a year after
the first cancer treatment and in a control group. Patients with recurrence of
the tumour were excluded. The control patients and patients after breast,
colo-rectal and gynaecological cancer were obtained from the database of the
Northern Centre for Health Care Research (NCG). The control group was
matched for gender and age with the cancer group and lived in the same area
as the patients with cancer. Patients with head and neck cancer were assessed
in the University Hospital Groningen on the Department of oral and
maxillofacial surgery, the Department of otorhinolaryngology head & neck
surgery or on the Department of surgical oncology. The CES-D was assessed
during a regular appointment on the out patients clinic. Patients received a
letter, a week before their appointment in which the study was explained.
The medical doctor asked the patients to participate. If patients were willing
to participate an informed consent was signed, and the CES-D was filled out.
For the statistical analyses SPSS 10.0 was used. Of the CES-D the total
score, the somatic retarded activity score and the depressed affect score were
analysed. Because the other domains, positive affect and interpersonal affect,
were not relevant for this study these were not analysed.  
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An ANOVA multi-comparison between groups was performed for the
control and cancer group on the domain somatic retarded activity. An
A NOVA multi-comparison between groups with an Bonferroni post hoc
analyses was performed for the control group and four cancer groups. A
Kruskal-Wallis tests and median tests was performed. These ordinal tests
were performed as control for the outcome on the ANOVA multi
comparison tests because the outcomes on the CES-D are not normally
divided data. Also regression analyses were performed of the CES-D total
score, the somatic retarded activity score and the depressed affect score. 
Table 1  Descriptive data of the control group and the cancer groups, and the 













255 206 136 69 155
Female 68% (173) 99% (205) 44 % (60) 100 %(69) 33 %(51)
Age mean (SD) 58 (15) 55 (13) 66 (12) 53 (16) 61(12) 
Surgery - 99% (203) 100% (136) 96 % (66) 100% (155) 
Radiation therapy - 55% (114) 10% (13) 45 % (31) 69% (107)





11% (28) 21% (43) 5% (7) 20 % (14) 16% (25)
* Patients with a score of 16 or higher on the CES-D are at risk for depression.
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Results
Data of 566 patients and of 255 randomly chosen control patients were
analysed. The descriptive data are presented in Table 1. The breast and
gynaecological patients were mainly females. The patients at risk for a
possible depression according to the CES-D (score ≥16) are presented in
Table 1.
In table 2 the results of the ANOVA multi-comparison between groups are
presented. The cancer group differs significantly from the control group on
the domain somatic retarded activity, and depressed affect. The four cancer
groups and control group were also significantly different on total score,
somatic retarded activity, and depressed affect score (Table 2). The ANOVA
with a post-hoc bonferroni analyses (Table 3) shows the differences between
the control group and four cancer groups on the domain somatic retarded
activity. The colo-rectal patients score significantly lower compared to the
breast and head and neck patients. Because the outcomes on the CES-D are
not normally divided, we performed a Kruskal-Wallis test to analyse the
differences between the cancer groups and the control group. In the ranking
of the Kruskal Wallis the colo-rectal patients scored the lowest on all
outcome. Head and neck patients and breast patients scored highest for
somatic retarded activity. The total score, the somatic retarded activity score
and depressed affect score are significantly (p < 0.01) different for cancer
groups and control group. This significant difference was also found after a
median test. The outcome on the Kruskal Wallis test and the median test
were similar to the outcome on the ANOVA multi comparison .
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Table2  Mean scores on the CES-D total, the domains somatic retarded activity (7 items), and 
 depressed affect (5 items). Presented are the ANOVA multi comparison between groups (control – cancer) 








Control group 8.3 (6.4) 2.3 (2.6) 1.0 (1.7)
Cancer group total 9.0 (8.5) 1.3 .26 3.0 (3.4) 7.5 .006 1.6 (2.5) 12.1 .001
Control group 8.3 (6.4) 2.3 (2.6) 1.0 (1.7)
       Breast   10.5 (8.3)  3.3 (3.2)   1.9 (2.6)
       Colo-rectal   7.0   (6.7)  1.7 (2.4)   0.9 (1.8)
       Gynaecological   9.4   (9.6)  2.6 (3.5)   1.9 (3.0)
       Head and Neck   8.3   (8.9) 4.2 .002  3.8 (4.0) 8.7 .000   1.5 (2.4) 7.1 .000
Table 3  An ANOVA multi-comparison with post-hoc analyses with a Bonferroni correction was 
  performed for the four cancer types and the control group for the domain somatic retarded activity. 
  In the cells the p values for the differences are shown.
Control Breast Colo-rectal Gynaecological
Breast .02 < 0.01 1.0
Colo-rectal 1.0 < 0.01 .88
Gynaecological 1.0 1.0 .88
Head and Neck < 0.01 1.0 < 0.01 .20
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In the regression analyses we estimated the mean CES-D total score, somatic
retarded activity and depressed affect as dependent of the variables cancer
types, age and gender (Table 4). 
Somatic retarded activity is related to breast cancer, and head and neck
cancer as well as gender. Gender was related to all outcome. Colo-rectal
cancer was excluded in all analyses.
 
Table 4 Regression analyses for CES-D total, somatic 
 retarded activity and depressed affect. 





























Cancer patients are not a homogeneous group of patients with respect to the
outcome of the CES-D and the domains somatic retarded activity and
depressed affect. In comparison with a control group cancer patients score
lower (colo-rectal) as well as higher (breast, and head & neck) on the
domain somatic retarded activity. Therefor removing somatic items in a
depression questionnaire to assess cancer patients seems not valid. The
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influence of gender is also in cancer patients important and strongly related
to cancer type (Weissman et al., 1993). 
We can assume that regarding to somatic sequela “the cancer patient” does
not exist. Cancer patients have similarities, like everyone has to cope with a
life threatening disease, interruption of normal daily life, and being exposed
to treatments, but there are also differences like type of treatment, place of
surgery and radiation therapy, the severity of the cancer, the extensiveness of
the treatment and the extent of sacrificed structures. As a consequence the
somatic morbidity after cancer treatments is different. Especially the place of
the tumour seems important. For instance the surgical removal of a tumour
of the tong including removing of salivary glands, a neck dissection and
radiation therapy of the neck, has more somatic consequences than removing
the uterus or a part of colon without radiation therapy. These differences in
treatment have consequences on somatic morbidity and probably also on the
results on the somatic items assessed by a depression questionnaire.  
In the analyses between the complete cancer group and the control group the
hypothesis that somatic morbidity is affecting the prevalence of depression
after cancer treatment seems true. In the multi comparison although only
head and neck cancer and breast cancer score high on the somatic domain.
Somatic morbidity might increase the prevalence of depression in these
groups. This could implicate that in these groups the somatic domain or
specific somatic items should be removed. This opportunity seems not valid,
because we don’t know which specific items should be removed and
removing all somatic items seems conflicting with the construction of
depression.  
Breast and gynaecological patients are mainly women, the female gender has
an important impact on the CES-D total scores. The percentages of patients
at risk for depression are the highest in these two patient groups. Also the
scores on depressed affect are the highest in these two groups. Head and
neck patients score significantly higher on the somatic retarded activity
domain. Patients with head and neck cancer often have to undergo extensive
surgery. This might contain sacrificing part of the glottis, removing salivary
glands, removing the upper trachea (getting a tracheostoma), or removing a
part of the mandibula possible restored with part of the fibula bone. These
extensive operation seem to clarify the high somatic morbidity rates. 
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The use of questionnaires to assess depression in the medical setting seems
valuable because of the high prevalence of depression. Physicians are not
well trained in recognising depressions (Passik et al., 2000), therefor a
questionnaire can be a helpful tool to explore a possible depression during
the medical follow up. If patients score high on a CES-D a referral to a
psychologists, social worker or a peer group must be considered to the
patient. If a score is around 16 the physician should further explore the
patient by asking specific questions that focus on a depressed mood. 
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